Roger Tuen is CEO of Amicoat. Mr. Tuen brings more than 20 years of international life science experience in commercial, business development and general management roles in listed companies. He has negotiated several licensing agreements with multinational and regional companies, and managed strategic alliances and partnerships throughout his carrier. He holds a MSc Pharm from the University of Oslo and a MBA from the Norwegian School of Management and ESCP-EAP, France.
Dr. Svendsen brings extensive research experience in medical biochemistry, synthetic organic chemistry and medicinal chemistry, specializing in antibacterial peptides. Dr. Svendsen received his PhD from the University of Tromsø, and has been visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at Massachusetts Institute of Technology. He is a Professor of organic chemistry in the Faculty of Sciences at the University of Tromsø. Dr. Svendsen is also a co-founder and board member of Lytix Biopharma AS, a Norwegian pharmaceutical company focusing on cancer immunotherapy.
Pontus Lundberg is VP R&D and brings experience in designing materials for biomedical applications both from industry and academia. His academic background includes a MSc in chemical engineering from Uppsala University and a PhD in polymer chemistry from KTH Royal Institute of Technology in Stockholm. Followingly, he spent 2 years as postdoctoral scholar at UC Santa Barbara. Most recently Pontus worked for Thermo Fisher Scientific for nearly 10 years in R&D both as a researcher and in management.
Kjetil Vangsnes is CFO of Amicoat and is responsible for finance and administration. Vangsnes holds an MBA from INSEAD and an MSc from the Norwegian School of Economics. He brings with him a wide experience from industry, life science, oil services, and shipping. Vangsnes has 20 years experience as CFO in listed and non- listed companies. He has mainly worked in international settings and has experience from Norwegian, US (GE Healthcare) and French (Technip) group constellations. He has held overall financial responsibilities and has been a board member in companies in Norway and abroad.
Njål Tage Gjerdalen, Director Business Development
Gjerdalen has six years experience from national and international leadership roles in the pharmaceutical company Sanofi. He managed two business areas for Sanofi in Norway and has broad experience in analysis, sales, marketing and management.
He is educated doctor at the University of Oslo and has unique expertise and experience in the interface between medicine and business.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
